Genflow reports sustained safety in aged dog gene therapy trial
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
LONDON - Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) reported that its SIRT6 gene therapy maintained safety and efficacy three months after dosing in its ongoing SLAB clinical trial in aged beagles, according to a press release statement issued today.
Read full article at source